Oral delivery of lactoferrin: A Review

International Journal of Peptide Research and Therapeutics

Volumn 19, Issue 2, 2013, Pages 125-134

  Yao, Xudong ^a   Bunt, Craig ^b   Cornish, Jillian ^c   Quek, Siew Young ^d   Wen, Jingyuan ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b LINCOLN UNIVERSITY   (New Zealand)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Chitosan; Gastrointestinal tract (GIT); Lactoferrin (Lf); Liposomes; Nanoparticles; PEGylation

Indexed keywords

ALGINIC ACID; APROTININ; ARGINYLGLYCYLASPARTIC ACID; BACITRACIN; BORONIC ACID DERIVATIVE; BOWMAN BIRK INHIBITOR; BUSERELIN; CHITOSAN; CITRIC ACID; CYCLODEXTRIN; CYCLOSPORIN A; DEXTRAN SULFATE; DODECYL SULFATE SODIUM; EDETIC ACID; INSULIN; LACTOFERRIN; LIPOSOME; MACROGOL; METKEPHAMID; NANOPARTICLE; NANOSPHERE; OCTANOIC ACID; POLYGLACTIN; POLYLACTIC ACID; SALCATONIN; SALICYLIC ACID; SK AND F 106760; SOYBEAN TRYPSIN INHIBITOR; TAUROCHOLIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG FORMULATION; DRUG HALF LIFE; DRUG STABILITY; EDEMA; HUMAN; LIPOSOMAL DELIVERY; LIVER INJURY; LIVER PROTECTION; MICROEMULSION; NANOTECHNOLOGY; NONHUMAN; PHYSICAL CHEMISTRY; UNSPECIFIED SIDE EFFECT;

EID: 84877981358     PISSN: 15733149     EISSN: 15733904     Source Type: Journal    
DOI: 10.1007/s10989-012-9326-8     Document Type: Article

References (131)

1. Acero-Lopez A, Schell P, Corredig M, Alexander M (2010) Characterization of lactoferrin oil in water emulsions and their stability in recombined milk. J Dairy Res 77:445-451
2. Appelmelk BJ, An YQ, Geerts M, Thijs BG, de Boer HA, MacLaren DM, de Graaff J, Nuijens JH (1994) Lactoferrin is a lipid A-binding protein. Infect Immun 62:2628-2632
3. Attwood D, Mallon C, Ktistis G, Taylor CJ (1992) A study on factors influencing the droplet size in nonionic oil-in-water microemulsions. Int J Pharm 88:417-422
4. Balthasar S, Michaelis K, Dinauer N, Von BH, Kreuter J, Langer K (2005) Preparation and characterisation of antibody modified gelatin nanoparticles as drug carrier system for uptake in lymphocytes. Biomaterials 26:2723-2732
5. Berkhout B, Floris R, Recio I, Visser S (2004) The antiviral activity of the milk protein lactoferrin against the human immunodeficiency virus type 1. Biometals 17:291-294
6. Bernkop-Schnurch A (1998) The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins. J Control Release 52:1-16
7. Bernkop-Schnurch A, Clausen A (2002) Biomembrane permeability of peptides: strategies to improve their mucosal uptake. Mini Rev Med Chem 2:295-305
8. Bernkop-Schnurch A, Krajicek ME (1998) Mucoadhesive polymers as platforms for peroral peptide delivery and absorption: synthesis and evaluation of different chitosan-EDTA conjugates. J Control Release 50:215-223
9. Bernkop-Schnurch A, Schmitz T (2007) Presystemic metabolism of orally administered peptide drugs and strategies to overcome it. Curr Drug Metab 8:509-517
10. Bernkop-Schnurch A, Paikl C, Valenta C (1997) Novel bioadhesive chitosan-EDTA conjugate protects leucine enkephalin form degradation by aminopeptidase N. Pharm Res 14(7):917-922
11. Bernkop-Schurch A, Hoffer MH, Kafedjiiski K (2004) Thiomers for oral delivery of hydrophilic macromolecular drugs. Expert Opin Drug Deliv 1(1):87-98
12. Borchard RT (1999) Optimising oral absorption of peptides using prodrug strategies. J Control Release 62:231-238
13. Brock JH, Arzabe F, Lampreave F, Pineiro A (1976) The effect of trypsin on bovine transferrin and lactoferrin. Biochim Biophys Acta 446:214-225
14. Cho YW, Flynn M (1989) Oral delivery of insulin. Lancet 2:1518-1519
15. Cilek A, Celebi N, Tirnaksiz F, Tay A (2005) A lecithin-based microemulsion of rh-insulin with aprotinin for oral administration: investigation of hypoglycemic effects in non-diabetic and STZ-induced diabetic rats. Int J Pharm 298:176-185
16. Colonna C, Genta I, Perugini P (2006) 5-Methyl-pyrrolidinone chitosan films as carriers for buccal administration of proteins. AAPS Pharm Sci Tech 7(3):107-113
17. Constantinides PP, Scalart JP, Lancaster C, Marcello J, Marks G, Ellens H, Smith PL (1994) Formulation and intestinal absorption enhancement evaluation of water-in-oil microemulsions incorporating medium-chain glycerides. Pharm Res 11:1385-1390
18. Cornish J, Palmano K, Callon KE, Watson M, Lin JM, Valenti P, Naot D, Grey AB, Reid IR (2006) Lactoferrin and bone: structure-activity relationships. Biochem Cell Biol 84:297-302
19. Cui F, Zhang L, Zheng J, Kawashima Y (2004) A study of insulin-chitosan complex nanoparticles used for oral administration. STP Pharma 14(6):435-439
20. Danielsson I, Lindman B (1981) The definition of microemulsion. Colloids Surf 3:391-392
21. Ekwuribe NN, Ramaswamy M, Radhakrishnan B, Allaudeen HSS (2001) US20016191105
22. Eliassen LT, Berge G, Sveinbjornsson B, Svendsen JS, Vorland LH, Rekdal O (2002) Evidence for a direct antitumor mechanism of action of bovine lactoferricin. Anticancer Res 22:2703-2710
23. Ellison RT, Giehl TJ (1991) Killing of gram-negative bacteria by lactoferrin and lysozyme. J Clin Invest 88:1080-1091
24. El-Shabouri MH (2002) Positively charged nanoparticles for improving the oral bioavailability of cyclosporin A. Int J Pharm 249:101-108
25. Figueiras A, Hombach J, Veiga F, Bernkop-Schnurch A (2008) In vitro enhancing effect of 1-dodecylazacycloheptan-2-evaluation of natural and methylated cyclodextrins as buccal permeation enhancing system for omeprazole delivery. Eur J Pharm Biopharm 72(3):561-566
26. Fisher R, Debbabi H, Blais A, Dubarry M, Rautureau M, Boyaka PN, Tome D (2007) Uptake of ingested bovine lactoferrin and its accumulation in adult mouse tissue. Int Immunopharmacol 7:1387-1393
27. Fujii S, Yokoyama T, Ikegaya K, Sato F, Yokoo N (1985) Promoting effect of the new chymotrypsin inhibitor FK-448 on the intestinal absorption of insulin in rats and dogs. J Pharm Pharmacol 37:545-549
28. Fukunga M, Miller MM, Deftos LJ (1991) Liposome-entrapped calcitonin and parathyroid hormone are orally effective in rats. Horm Metab Res 23:166-167
29. Galindo-Rodriguez SA, Allemann E, Fessi H, Doelker E (2005) Polymeric nanoparticles for oral delivery of drugs and vaccines: a critical evaluation of in vivo studies. Crit Rev Ther Drug Carr Syst 22:419-464
30. Gan ZH, Yu DH, Zhong ZY, Liang QZ, Jing XB (1999) Enzymatic degradation of poly(epsilon-caprolactone)/poly(d,l-lactide) blends in phosphate buffer solution. Polymer 40:2859-2862
31. Gao ZG, Choi HG, Shin HJ, Park KM, Lim SD, Hwang KJ, Kim CK (1998) Physicochemical characterization and evaluation of a microemulsion system for oral delivery of cyclosporin A. Int J Pharm 161:75-86
32. Garcia-Fuentes M, Prego C, Torres D, Alonso MJ (2005) A comparative study of the potential of solid triglyceride nanostructures coated with chitosan or poly (ethylene glycol) as carriers for oral calcitonin delivery. Eur J Pharm Sci 25:133-143
33. Gentilucci L, Marco RD, Cerisoli L (2010) Chemical modifications designed to improve peptide stability: incorporation of non-natural amino acids, pseudo-peptide bonds, and cyclization. Curr Pharm Des 16:3185-3203
34. Hayashida K, Kaneko T, Takeuchi T, Shimizu H, Ando K, Harada E (2004) Oral administration of lactoferrin inhibits inflammation and nociception in rat adjuvant-induced arthritis. J Vet Med Sci 66:149-154
35. Hejazi R, Amiji M (2003) Chitosan-based gastrointestinal delivery systems. J Control Release 89:151-165
36. Hoogstraate AJ, Senel S, Cullander C (1996) Effects of bile salts on transport rates and routes of FTIC-labelled compounds across porcine buccal epithelium in vitro. J Control Release 40:211-221
37. Hu K, Li JW, Shen YH, Lu W, Gao XL, Zhang QZ, Jiang XG (2009) Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations. J Control Release 134:55-61
38. Huang SW, Satue-Gracia MT, Frankel EN, German JB (1999) Effect of lactoferrin on oxidative stability of corn oil emulsions and liposomes. J Agric Food Chem 47(4):1356-1361
39. Huang RQ, Ke WL, Liu Y, Jiang Y, Jiang C, Pei YY (2008) The use of lactoferrin as a ligand for targeting the polyamidoamine based gene delivery system to the brain. Biomaterials 29:238-246
40. Huang RQ, Ke WL, Han L, Liu Y, Shao K, Ye LY, Lou JN, Jiang C, Pei YY (2009) Brain-targeting mechanisms of lactoferrin-modified DNA-loaded nanoparticles. J Cerebral Blood Fow Metab 19:1914-1923
41. Huang RQ, Ke WL, Han L, Liu Y, Shao K, Jiang C, Pei YY (2010) Lactoferrin modified nanoparticles could mediate efficient gene delivery to the brain in vivo. Brain Res Bull 81:600-604
42. IIIum L (1998) Chitosan and its use as a pharmaceutical excipient. Pharm Res 15:1326-1331
43. Ishikado A, Imanaka H, Tekeuchi T, Harada E, Makino T (2005) Liposomalization of lactoferrin enhanced it's anti-inflammatory effects via oral administration. Biol Pharm Bull 28:1717-1772
44. Ishikado A, Uesaki S, Suido H, Nomura Y, Sumikawa K (2010) Human trial of liposomal lactoferrin supplementation for periodontal. Biol Pharm Bull 33:1758-1762
45. Johansson BG (1960) Isolation of an iron containing red protein from human milk. Acta Chem Scand 14:510-512
46. Junginger HE, Verhoef JC (1998) Macromolecules as safe penetration enhancers for hydrophilic drugs - a fiction. Pharm Sci Tech Today 1:370-376
47. Karthikeyan S, Paramasivam M, Yadav S, Srinivasan A, Singh TP (1999) Structure of buffalo lactoferrin at 2.5 Å resolution using crystals grown at 303 K shows different orientations of the N and C lobes. Acta Crystallogr D Biol Crystallogr 55:1805-1813
48. Kato K, Tamaki N, Saito Y, Fujimoto T, Sato A (2010) Amino group PEGylation of bovine lactoferrin by linear polyethylene glycol-p-nitrophenyl active ester. Biol Pharm Bull 33(7):1253-1255
49. Khan JA, Kumar P, Paramasivam M, Yadav RS, Sahani MS, Sharma S, Srinivasan A, Singh TP (2001) Camel lactoferrin, a transferrin-cum-lactoferrin: crystal structure of camel apolactoferrin at 2.6 Å resolution and structural basis of its dual role. J Mol Biol 309:751-761
50. Kimura T, Sato K, Sugimoto K, Tao R, Murakami T, Kurosaki Y, Nakayama T (1996) Oral administration of insulin as poly (vinyl alcohol)-gel spheres in diabetic rats. Biol Pharm Bull 19:897-900
51. Kraeling ME, Ritschel WA (1992) Development of a colonic release capsule dosage form and the absorption of insulin. Methods Find Exp Clin Pharmacol 14:199-209
52. Kreuter J (1994) Nanoparticles. In: Kreuter J (ed) Colloidal drug delivery systems. Marcel Dekker Inc., New York, pp 219-242
53. Kuwata H, Yamauchi K, Teraguchi S, Ushida Y, Shimokawa Y, Toida T, Hayasawa H (2001) Functional fragments of ingested lactoferrin are resistant to proteolytic degradation in the gastrointestinal tract of adult rats. J Nutr 131:2121-2127
54. Langguth P, Bohner V, Biber J, Merkle HP (1994) Metabolism and transport of the pentapeptide metkephamid by brush-border membrane vesicles of rat intestine. J Pharm Pharmacol 46:34-40
55. Langoth N, Bernkop-Scnhurch A, Kurka P (2005) In vitro evaluation of various buccal permeation enhancing systems for PACAP (pituitary adenylate cyclase-activating polypeptide). Pharm Res 22:2045-2050
56. Lee VHL, Traver RD, Taub ME (1991) Enzymatic barriers to peptide and protein drug delivery. In: Lee VHL (ed) Peptide and protein drug delivery. Marcel Dekker Inc., New York, pp 303-358
57. Leroueil-Le VM, Fluckiger L, Kim YI, Hoffman M, Maincent P (1998) Preparation and characterization of nanoparticles containing an antihypertensive agent. Eur J Pharm Biopharm 46:137-143
58. Lesme U, Baudot P, McClements DJ (2010) Impact of interfacial composition on physical stability and in vitro lipase digestibility of triacylglycerol oil droplets coated with lactoferrin and/or caseinate. J Agric Food Chem 58:7962-7969
59. Lian DH, Xing T, Fu DC (2004) Solid lipid nanoparticles to improve oral bioavailability of poorly soluble drugs. J Pharm Pharmacol 56:1527-1535
60. Lueben HL, De Leeuw BJ, Langemeyer MWE, De Boer AG, Verhoef JC, Junginger HE (1996) Mucoadhesive polymers in peroral peptide drug delivery. VI. Carbomer and chitosan improve the intestinal absorption of the peptide drug buserelin in vivo. Pharm Res 13:1668-1672
61. Mahato RI, Narang AS, Thoma L (2003) Emerging trends in oral delivery of peptide and protein drugs. Crit Rev Ther Drug Carrier Syst 20:153-214
62. Maitani Y, Hazama M, Tojo Y, Shimoda N, Nagai T (1996) Oral administration of recombinant human erythropoietin in liposomes in rats: influence of lipid composition and size of liposomes on bioavailability. J Pharm Sci 85:440-445
63. Marchetti M, Superti F, Ammendolia MG, Rossi P, Valenti P, Seganti L (1999) Inhibition of poliovirus type 1 infection by iron-, manganese- and zinc-saturated lactoferrin. Med Microbiol Immunol 187:199-204
64. McClellan JB, Garner CW (1998) Purification and properties of human intestine alanine aminopeptidase. Biochim Biophys Acta 613:60-167
65. Melmed RN, El-Aaser AA, Holt SJ (1976) Hypertrophy and hyperplasia of the neonatal rat exocrine pancreas induced by orally administered soybean trypsin inhibitor. Biochim Biophys Acta 421(2):280-288
66. Mikogami T, Heyman M, Spik G, Desjeux JF (1994) Apical-to-basolateral transepithelial transport of human lactoferrin in the intestinal cell line HT-29cl.19A. Am J Physiol 267:308-315
67. Moore SA, Anderson BF, Groom CR, Harides M, Baker EN (1997) Three-dimensional structure of diferric bovine lactoferrin at 2.8 Å resolution. J Mol Bio 274:222-236
68. Morel S, Ugazio E, Cavalli R, Gaosco MR (1996) Thymopentin in solid lipid nanoparticles. Int J Pharm 132:259-261
69. Muller RH, Runge S, Ravelli V, Mehnert W, Thunemannc AF, Souto EB (2006) Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN®) versus drug nanocrystals. Int J Pharm 317:82-89
70. Murphy ME, Kariwa H, Mizutani T, Tanabe H, Yoshimatsu K, Arikawa J, Takashima I (2001) Characterization of in vitro and in vivo antiviral activity of lactoferrin and ribavirin upon hantavirus. J Vet Med Sci 63:637-645
71. Naicker SA, Yatscoff RW, Foster RT (2006) US20067060672
72. Narang AS, Delmarre D, Gao D (2007) Stable drug encapsulation in micelles and microemulsions. Int J Pharm 345:9-25
73. Nielsen NS, Petersen A, Meyer AS, Timm-Heinrich M, Jacobsen C (2004) Effects of lactoferrin, phytic acid, and EDTA on oxidation in two food emulsions enriched with long-chain polyunsaturated fatty acids. J Agric Food Chem 52(25):7690-7699
74. Nishihata T, Kim S, Morishita S (1983) Adjuvant effects of glyceryl esters of acetoacetic acid on rectal absorption of insulin and inulin in rabbits. J Pharm Sci 72:280-285
75. Noh GJ, Lee EH, Lee SH, Park DY, Ki KH, Lee EK, Lee DH (2008) Physicochemical properties, pharmacokinetics, and pharmacodynamics of a reformulated microemulsion propofol in rats. Anaesthesiology 109:436-447
76. Nojima Y, Suzuki Y, Iguchi K, Shiga T, Iwata A, Fujimoto T, Yoshida K, Shimizu H, Takeuchi T, Sato A (2008) Development of PEG conjugated lactoferrin for oral administration. Bioconjugate Chem 19:2253-2259
77. Nojima Y, Suzuki Y, Yoshida K, Abe F, Shiga T, Takeuchi T, Sugiyama A, Shimizu H, Sato A (2009) Lactoferrin conjugated with 40-kDA branched PEG has and improved circulating half-life. Pharm Res 26:2125-2132
78. Norris DA, Puri N, Sinko PJ (1998) The effect of physical barriers and properties on the oral absorption of particulates. Adv Drug Deliv Rev 34:135-154
79. Onishi H, Machida Y, Koyama K (2007) Preparation and in vitro characteristics of lactoferrin loaded chitosan microparticles. Drug Dev Ind Pharm 33:641-647
80. Onishi H, Koyama K, Sakata O, Machida Y (2009) Preparation and in vitro evaluation of chitosan-coated alginate/calcium complex microparticles loaded with fluorescein-labeled lactoferrin. Yakugaku Zasshi 129(12):1507-1514
81. Onishi H, Koyama K, Sakata O, Machida Y (2010) Preparation of chitosan/alginate/calcium complex microparticles loaded with lactoferrin and their efficacy on carrageenan-induced edema in rats. Drug Dev Ind Pharm 36(8):879-884
82. Oosegi T, Onishi H, Machida Y (2008) Novel preparation of enteric-coated chitosan-prednisolone conjugate microspheres and in vitro evaluation of their potential as a colonic delivery system. Eur J Phram Biopharm 68(2):260-266
83. Owen AJ, Yiv SH (1997) US5646109
84. Pan Y, Li YJ, Zhao HY (2002) Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo. Int J Pharm 249:139-147
85. Penkler L, Muller RH, Runger SA, Ravelli V (1999) Pharmaceutical cyclosporin formulation with improved biopharmaceutical properties, improved physical quality and greater stability, and method for producing said formulation. PCT-application PCT/EP99/02892
86. Pierce A, Colavizza D, Benaissa M, Maes P, Tartar A, Montreuil J, Spik G (1991) Molecular cloning and sequence analysis of bovine lactotransferrin. Eur J Biochem 196:177-184
87. Portero A, Remunan-Lopez C, Nielsen HM (2002) The potential of chitosan in enhancing peptide and protein absorption across TR146 cell culture model-an in vitro model of the buccal epithelium. Pharm Res 19:169-174
88. Prego C, Torres D, Fernandez-Megia E, Novoa-Carballal R, Quinoa E, Alonso MJ (2006) Chitosan-PEG nanocapsules as new carriers for oral peptide delivery effect of chitosan pegylation degree. J Control Release 111:299-308
89. Raehs SC, Sandow J, Wirth K, Merkle HP (1988) The adjuvant effect of bacitracin on nasal absorption of gonadorelin and buserelin in rats. Pharm Res 5:689-693
90. Rejman J, Oberle V, Zuhorn IS, Hoekstra D (2004) Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J 377:159-169
91. Reseland JE, Holm H, Jacobsen MB, Jenssen TG, Hanssen LE (1996) Proteinase inhibitors induce selective stimulation of human trypsin and chymotrypsin secretion. Hum Clin Nutr 126:634-642
92. Ringe K, Walz CM, Sabel BA (2004) Nanoparticle drug delivery to the brain. In: Nalwa HS (ed) Encyclopedia of nanoscience and nanotechnology, vol 7. American Scientific Publishers, Stevenson Ranch, pp 91-104
93. Roberts MJ, Bentley MD, Harris JM (2002) Chemistry for peptide and protein PEGylation. Adv Drug Del Rev 54:459-476
94. Roseanu A, Florian PE, Moisei M, Sima LE, Evans RW, Trif ML (2010) Liposomalization of lactoferrin enhanced its anti-tumoral effects on melanoma cells. Biometals 23:485-492
95. Russel-Jones GJ (2001) The potential use of receptor-mediated endocytosis for oral drug delivery. Adv Drug Deliv Rev 46:59-73
96. Saffran M, Bedra C, Kumar GS, Neckers DC (1988) Vasopressin: a model for the study of effects of additives on the oral and rectal administration of peptide drugs. J Pharm Sci 77:33-38
97. Sakuma S, Suzuki H, Kikuchi H, Hiwatari KI, Arikawa K, Kishida A, Akashi M (1997) Oral peptide delivery using nanoparticles composed of novel graft copolymers having hydrophobic backbone and hydrophilic branches. Int J Pharm 149:93-106
98. Schryvers AB, Morris LJ (1988) Identification and characterization of the human lactoferrin-binding protein from Neisseria meningitidis. Infect Immun 56:1144-1149
99. Shantha Kuma TR, Soppomath K, Nachaegari SK (2006) Novel delivery technologies for protein and peptide therapeutic. Curr Pharm Biotechnol 7:261-276
100. Sharma AK, Karthikeyan S, Sharma S, Yadav S, Srinivasan A, Singh TP (1998) Structures of buffalo and mare lactoferrins. Similarities, differences, and flexibility. Adv Exp Med Biol 443:15-21
101. Sharma P, Chawla HPS, Panchagnula R (1999) The role of sorption promoters in increasing the bioavailability of drugs in oral preparations. Drugs Future 24:1221-1240
102. Shiota M, Uchida T, Oda T, Kawakami H (2006) Utilization of lactoferrin as an iron-stabilizer for soybean and fish oil. J Food Sci 71(3):C120-C123
103. Siegel IA, Gordon HP (1985) Effects of surfactants on the permeability of canine oral mucosa in vitro. Toxicol Lett 26:153-158
104. Soerensen M, Soerensen SPL (1939) The protein in whey. C R Trav Lab Carlsberg 23:55-99
105. Spangler RS (1990) Insulin administration via liposomes. Diabetes Care 13:911-922
106. Spernath A, Aserin A (2006) Microemulsions as carriers for drugs and nutraceuticals. Adv Colloid Interface Sci 128:47-64
107. Sudhakar Y, Kuotsu K, Bandyopadhyay AK (2006) Buccal bioadhesive drug delivery - a promising option for orally less efficient drug. J Control Release 114:15-40
108. Sugiyama A, Sato A, Takeuchi T (2009) PEGylated lactoferrin enhanced its hepatoprotective effects on acute liver injury induced by carbon tetrachloride in rats. Food Chem Toxicol 47(7):1453-1456
109. Sushama T, Adnan A, Farhan JA, Roop KK, Shadab AP, Zeenat IK (2008) Microemulsion: a novel approach to enhanced drug delivery. Rec Pat on Drug Deliv Formul 2:238-257
110. Takakura N, Wakabayashi H, Ishibashi H, Teraguchi S, Tamura Y, Yamaguchi H, Abe S (2003) Oral lactoferrin treatment of experimental oral candidiasis in mice. Antimicrob Agents Chemother 47:2619-2623
111. Takeuchi H, Yamamoto H, Niwa T, Hino T, Kawashima Y (1994) Mucoadhesion of polymer-coated liposomes to rat intestine in vitro. Chem Pharm Bull 42:1954-1956
112. Takeuchi H, Yamamoto H, Niwa T, Hino T, Kawashima Y (1996) Enteral absorption of insulin in rats. Pharm Res 13:896-901
113. Takeuchi H, Matsui Y, Yamamoto H, Kawashima Y (2003) Mucoadhesive properties of carbopol or chitosan-coated liposomes and their effectiveness in the oral administration of calcitonin to rats. J Control Release 86:235-242
114. Teraguchi S, Wakabayashi H, Kuwata H, Yamauchi K, Tamura Y (2004) Protection against infection by oral lactoferrin: evaluation in animal model. Bometals 17:231-234
115. Thanou M, Verhoef JC, Marbach P, Junginger HE (2000) Intestinal absorption of octreotide: N-trimethyl chitosan healing of chloride (TMC) ameliorates the permeability and absorption properties of the somatostatin analogue in vitro and in vivo. J Pharm Sci 89:951-957
116. Thirawong N, Thongborisute J, Takeuchi H, Sriamornsak P (2008) Improved intestinal absorption of calcitonin by mucoadhesive delivery of novel pectin-liposome nanocomplexes. J Control Release 125:236-245
117. Tomita M, Wakabayashi H, Yamauchi K, Teraguchi S, Hayasawa H (2002) Bovine lactoferrin and lactoferricin derived from milk: production and application. Biochem Cell Biol 80:109-112
118. Tomita M, Wakabayashi H, Shin K, Yamauchi K, Yaeshima T, Iwatsuki K (2009) Twenty-five years of research on bovine lactoferrin application. Biochimie 91:52-57
119. Troost FJ, Saris WHM, Brummer RJM (2002) Orally ingested human lactoferrin is digested and secreted in the upper gastrointestinal tract in vivo in women with ileostomies. J Nutr 132:2597-2600
120. Trull AK, Tan KK, Tan L, Alexander GJ, Jamieson NV (1995) Absorption of cyclosporin from conventional and new microemulsion oral formulations in liver transplant recipients with external biliary diversion. Br J Clin Pharmacol 39:627-631
121. Tsubery H, Mironchik M, Fridkin M, Shechter Y (2004) Prolong the action of protein and peptide drug by a novel approach of reversible polyethylene glycol modification. J Biol Chem 279:38118-38124
122. Tsuda H, Sekine K, Fujita K, Iigo M (2002) Cancer prevention by bovine lactoferrin and underlying mechanisms-a review of experimental and clinical studies. Biochem Cell Biol 80:131-136
123. Ushirogawa Y, Nakahigashi Y, Kiriyama A, Takada K (1992) Effect of organic acids, trypsin inhibitors and dietary protein on the pharmacological activity of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in rats. Int J Pharm 81:133-141
124. Utoguchi N, Watanabe Y, Shida T, Matsumoto M (1998) Nitric oxide donors enhance rectal absorption of macromolecules in rabbits. Pharm Res 15:870-876
125. Weinberg ED (2007) Antibiotic properties and application of lactoferrin. Curr Pharma Des 13:801-811
126. Yamamoto A, Taniguchi T, Rikyuu K, Tsuji T, Fujita T, Murakami M, Muranishi S (1994) Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats. Pharm Res 11:1496-1500
127. Yamano E, Miyauchi M, Furusya H, Kawazoe A, Ishikado A, Makino T, Tanne K, Tanaka E, Takata T (2010) Inhibitory effects of orally administrated liposomal bovine lactoferrin on the LPS-induced osteoclastogenesis. Lab Invest 90:1236-1246
128. Yamashita S, Saitoh H, Nakanishi K (1985) Characterization of enhanced intestinal permeability; electrophysiological study on the effects of diclofenac and ethylenediamine tetraacetic acid. J Pharm Pharmacol 37:512-513
129. Yuan JS, Ansari M, Samaan M (2008) Linker-based lecithin microemulsions for transdermal delivery of lidocaine. Int J Pharm 349(1-2):130-143
130. Zhang S, Uludag H (2009) Nanoparticulate systems for growth factor delivery. Pharm Res 26:1561-1580
131. Zhang N, Ping Q, Huang G, Xu W, Cheng Y, Han X (2006) Lectin modified solid lipid nanoparticles as carriers for oral administration of insulin. Int J Pharm 327:153-159